Phacilitate Leaders World

Conference speakers

Loading
Ron Smith

Ron Smith

Chief Commercial Officer, Spark Therapeutics

Ron Philip is Chief Commercial Officer of Spark Therapeutics and is responsible for leading commercial strategy & operations including marketing, sales, diagnostics, market access and patient services functions for inline products. He also manages commercial development activities for Spark’s late-stage pipeline assets. Ron has over 20 years of experience in the pharmaceutical industry with a proven track record of improving operating performance in multiple therapeutic categories and global markets.

Prior to joining Spark Therapeutics, he served in several senior leadership roles at Pfizer including Regional President – Africa Middle East, Head of Global Business Unit Strategy, Head of Business Development Search & Evaluation and Commercial Development within Pfizer’s Innovative Products Business. He previously worked at Wyeth Pharmaceuticals in U.S. commercial operations, with Deloitte Consulting in their strategy and operations practice and at Merck and Co. in the manufacturing and marketing divisions.  Ron is an alumnus of Drexel University. 

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK